Neoptolemos jp, dunn ja, stocken dd, almond j, link k, beger h, bassi c,

Prof. Dr. Rüdiger Hehlmann
Director III. Medizinische Klinik, Mannheim
III. Medizinische Klinik Medizinische Fakultät Mannheim der Universität Heidelberg Wiesbadener Str. 7-11 68305 Mannheim 0621 383 4115 (phone) 0621 383 4201 (fax) [email protected]
SCIENTIFIC VITA
Assistant, Max Planck Institute for Biochemistry, Munich Research Fellow, University of Rochester, New York, USA Research Associate, Columbia University, New York Lecturer in Human Genetics and Development at Columbia University Intern/Resident, Columbia-Presbyterian Medical Center Licence to practice Medicine and Surgery in the State of New York DFG (German Research Council)-stipend, Memorial Sloan Kettering Cancer Center Assistant at the Medizinische Universitätspoliklinik, Munich Major Postdoctoral Thesis (Habilitation) Tenured Professor (C2) at Munich University Full Professor of Medicine (C4) at the Mannheim Medical Faculty of the University of Heidelberg and Director of the III. Medizinische Universitätsklinik in Mannheim Secretary General of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) Chairman of the Competence Network “Acute and Chronic Leukemias” Chairman of the Network of Excellence “European LeukemiaNet” Curt-Bohnewand-Prize for cancer research (1984); GSF-Prize for interdisciplinary cooperation (1990); Paul Martini-Prize for improvement of treatment of chronic myeloid leukemia by a new prognostic score (2000). R.T. Silver-Lecture, Cornell University, New York (2004), Honorary Member of the Polish Society for Hematology and Transfusion Medicine (2005), Wiedermann-Lecture, Olmütz, Czechia (2006) FIELDS OF INTEREST
Mechanisms of carcinogenesis (retroviruses, chemicals, environment); mutation-proliferation vs. chromosomal hypotheses. Diagnosis and therapy of leukemias (CML, chronic myeloproliferative diseases, AML, molecular monitoring). Tyrosine kinase signalling and inhibition; mechanisms of resistance. Clinical trials in hematology and oncology. SELECTED PUBLICATIONS (SINCE 2000)

Hehlmann R, Hochhaus A, Baccarani M (2007). Seminar Chronic Myeloid Leukemia. Current
Management Issues and Recommendations on behalf of the European LeukemiaNet. Lancet, in
press
Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T,
Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C,
Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H,
Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A,
the SAKK and the German CML-Study Group (2007). Drug Treatment is Superior to Allografting as
First Line Therapy in Chronic Myeloid Leukemia. Blood, Epub 2007 Feb 22
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J,
Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H,
Larson R, Niederwieser D, Silver R, Hehlmann R (2006). Evolving concepts in the management of
chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European
Leukemianet. Blood. 108:1809-20
Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J,
Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J,
Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006). Monitoring CML patients
responding to treatment with tyrosine kinase inhibitors - Review and recommendations for
'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations
and for expressing results. Blood. 108, 28-37
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S,
Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ,
Hochhaus A, Hehlmann R, Chase A, Cross NC (2005). The t(8;9)(p22;p24) is a recurrent
abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65, 2662-2667
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH,
White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T,
Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005).
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood
106, 2162-2168
Hehlmann R, Berger U, Aul C, Büchner T, Döhner H, Ehninger G, Ganser A, Gökbuget N, Hoelzer
D, Überla K, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann
W, Ottmann OG, Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Böhme A, Harrison-
Neu E, Griesshammer M, Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B,
Niederwieser D, Heil G, Müller T, Hasford J (2004). The German competence network 'Acute and
chronic leukemias'. Leukemia 18, 665-669
Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A,
Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler
A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss
J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H (2003). Randomized
comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid
leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and
hydroxyurea. Leukemia 17, 1529-1537
Fabarius A, Willer A, Yerganian G, Hehlmann R, Duesberg P (2002). Specific aneusomies in
Chinese hamster cells at different stages of neoplastic transformation, initiated by
nitrosomethylurea. Proc Natl Acad Sci USA 99, 6778-83
Duesberg P, Stindl R, Hehlmann R (2001). Origin of multidrug resistance in cells with and without
multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad
Sci USA 98, 11283-11288

Source: http://translational-oncology.de/fileadmin/templates/pdf/hehlmannNEU.pdf